Literature DB >> 7843823

In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.

F H Kayser1.   

Abstract

The aim of our study was to re-evaluate the in vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics against bacteria causing respiratory tract infections. The study drugs were cefpodoxime, cefaclor, cefixime, cefuroxime, cefetamet, cefprozil, and the combination of amoxicillin and clavulanic acid (= augmentin). In addition, cefotaxime as the standard agent of parenteral third generation cephalosporins was examined. The organisms tested were Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, streptococci of serogroups C and G, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Proteus mirabilis. Minimal inhibitory concentrations of the antimicrobials were determined with the agar dilution procedure. Cefpodoxime showed the broadest spectrum and generally also the highest activity of the oral beta-lactam antibiotics examined. The drug was equally active against the major groups of beta-lactamase negative and positive bacteria causing respiratory tract infections. Against penicillin-resistant pneumococci, all beta-lactam agents exhibited reduced activity comparable to the reduced activity of penicillin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7843823     DOI: 10.1007/bf01715556

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  The Second European Collaborative Study on the frequency of antimicrobial resistance in Haemophilus influenzae.

Authors:  F H Kayser; G Morenzoni; P Santanam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

Review 3.  Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrhalis.

Authors:  R J Wallace; D R Nash; V A Steingrube
Journal:  Am J Med       Date:  1990-05-14       Impact factor: 4.965

4.  Antibiotic sensitivity of Streptococcus pneumoniae isolated from normally sterile body sites: first results of a multicenter study in Germany.

Authors:  R R Reinert; A Queck; A Kaufhold; M Kresken; R Lütticken
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

Review 5.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

6.  In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

7.  Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.

Authors:  H Knothe; P M Shah; O Eckardt
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

8.  In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

9.  Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.

Authors:  A Bauernfeind; R Jungwirth
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

Review 10.  Changes in the spectrum of organisms causing respiratory tract infections: a review.

Authors:  F H Kayser
Journal:  Postgrad Med J       Date:  1992       Impact factor: 2.401

  10 in total
  4 in total

Review 1.  Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.

Authors:  J A Balfour; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 2.  Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.

Authors:  B Fulton; C M Perry
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  The initial state of the human gut microbiome determines its reshaping by antibiotics.

Authors:  Frédéric Raymond; Amin A Ouameur; Maxime Déraspe; Naeem Iqbal; Hélène Gingras; Bédis Dridi; Philippe Leprohon; Pier-Luc Plante; Richard Giroux; Ève Bérubé; Johanne Frenette; Dominique K Boudreau; Jean-Luc Simard; Isabelle Chabot; Marc-Christian Domingo; Sylvie Trottier; Maurice Boissinot; Ann Huletsky; Paul H Roy; Marc Ouellette; Michel G Bergeron; Jacques Corbeil
Journal:  ISME J       Date:  2015-09-11       Impact factor: 10.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.